Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce new results showing its first-in-class PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma (EAC) with high accuracy.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announces the Preliminary Final Report and Annual Report.
In this edition of The Ellis Martin Report and Money Talk Radio, we sit down with Shaun Bagai, Chief Executive Officer of RenovoRx, Inc. (NASDAQ:RNXT), a clinical-stage biopharmaceutical company pioneering a targeted, localized approach to treat hard-to-reach cancers.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics and precision medicine, is pleased to provide the following update on its business activities for the three months to 30 June 2025 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the publication of results demonstrating the accuracy and performance of its next-generation PromarkerD test system.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce that in collaboration with The University of Western Australia, groundbreaking results demonstrate that the test for oxidative stress can identify muscle damage in Australian thoroughbred racehorses.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the assignment of billing code (0579U) by the American Medical Association (AMA) for the next-generation of the PromarkerD test system.
